Skip to content
6-K

Foreign Interim / Material

Kazia Therapeutics Limited. KZIA

0001213900-26-035886

← back to feed
Filed
Mar 30, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q2 2026 · Dec 31, 2025 1.56B sh
Shares Diluted Q2 2026 · Dec 31, 2024 425.16M sh
Operating Cash Flow Q2 2026 · Dec 31, 2025 −9.54M
Operating Cash Flow Q2 2026 · Dec 31, 2024 −8.42M
Cash And Equivalents Q2 2026 · Dec 31, 2025 69.46M
Cash And Equivalents Q2 2026 · Jun 30, 2025 4.34M
Cash And Equivalents Q2 2026 · Dec 31, 2024 3.06M
Cash And Equivalents Q2 2026 · Jun 30, 2024 1.66M
Stockholders Equity Q2 2026 · Dec 31, 2025 46.47M
Stockholders Equity Q2 2026 · Jun 30, 2025 −8.3M
Stockholders Equity Q2 2026 · Dec 31, 2024 −3.81M
Stockholders Equity Q2 2026 · Jun 30, 2024 −10.02M
Current Liabilities Q2 2026 · Dec 31, 2025 24.37M
Current Liabilities Q2 2026 · Jun 30, 2025 14.05M
Total Liabilities Q2 2026 · Dec 31, 2025 24.65M
Total Liabilities Q2 2026 · Jun 30, 2025 14.36M
Current Assets Q2 2026 · Dec 31, 2025 69.99M
Current Assets Q2 2026 · Jun 30, 2025 4.93M
Total Assets Q2 2026 · Dec 31, 2025 71.11M
Total Assets Q2 2026 · Jun 30, 2025 6.06M
Eps Diluted restated Q2 2026 · Dec 31, 2025 −0.81
Eps Diluted restated Q2 2026 · Dec 31, 2024 −2.46
Eps Basic restated Q2 2026 · Dec 31, 2025 −0.81
Eps Basic restated Q2 2026 · Dec 31, 2024 −2.46
Sga Expense Q2 2026 · Dec 31, 2025 8.56M
Sga Expense Q2 2026 · Dec 31, 2024 5.11M
Rd Expense Q2 2026 · Dec 31, 2025 4.99M
Rd Expense Q2 2026 · Dec 31, 2024 4.28M
Net Income Q2 2026 · Dec 31, 2025 −12.55M
Net Income Q2 2026 · Dec 31, 2024 −10.45M